PharmaTher’s Potential Breakthrough in Monkeypox Treatment

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd.’s subsidiary, Sairiyo Therapeutics, has discovered that cepharanthine may have the potential to combat monkeypox by binding to the virus’s proteins. This finding, from an independent drug screening study, suggests that cepharanthine could play a role in understanding and treating the virus. While promising, the company has clarified that there are no claims yet that cepharanthine can treat or cure monkeypox.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.